One study found that TAMs may promote the migration, invasion, and EMT of RCC cells through activation of the IL-6/STAT3 signaling pathway [49], which further indicates the potential of targeting IL-6 in TAMs for the treatment of progressive RCC. This evidence concerns the gene STAT3 and renal cell carcinoma.